Page 25 - Comprehensive treatment of patients with glucocorticoid-dependent severe asthma

45. Wenzel SE, Busse WW. Severe asthma: lessons from the Severe Asthma Research Program. J Allergy Clin Immunol 2007;119:14-21.
46. O’Neill S, Sweeney J, Patterson CC, Menzies-Gow A, Niven R, Mansur AH, Bucknall C, Chaudhuri R, Thomson NC, Brightling CE, O’Neill C, Heaney LG. The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry. Thorax 2015;70:376-378.
47. Lefebvre P. Acute and chronic systemic corticosteroid-related complications in patients with severe asthma. J Allergy Clin Immunol 2015; 136:1488-95.
48. Dalal et al. Dose response relantionship between long term systemic corticosteroid use and related complications in patients with severe asthma. J manag care pharm 2016;22:833-847.
49. Sarnes E, Crofford l, Watson M et al. incidence and US costs of corticosteroids-associated adverse events: a systematic literature review. Clin Ther 2011;33:1413.
50. Keenan GF. Management of complications of glucocorticoid therapy Clin Chest Med. 1997;18(3):507-20.
51. Saag KG, Furst DE. Major side effects of systemic glucocorticoids. https://www.uptodate.com/ contents/major-side-effects-of-systemic-glucocorticoids (last accessed December 2018)
52. Walsh LJ. Adverse effects of oral corticosteroids in relation to dose in patients with lung disease. Thorax 2001;56:279-84.
53. Volmer T, Effenberger T, Trautner C, Buhl R. Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in literature. Eur Respir J. 2018;52(4). pii: 1800703. doi: 10.1183/13993003.00703-2018. Print 2018 Oct.
54. Rice J.B, White A.G, et al. Long-term systemic corticosteroid exposure; a systematic literature review. Clinical therapeutics 2017;39:2216-2228.
55. Fardet L. Corticosteroid-induced adverse events in adults: frequency, screening and prevention. Drug safety 2007,30:861-81.
56. Van Staa. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 2003;48(11):3224-9.
57. Patten SB, Neutel CI. Corticosteroid-induced adverse psychiatric effects: incidence, diagnosis and management. Drug Saf 2000;22(2):111-22.
58. Warrington TP, Bostwick JM. Psychiatric adverse effects of corticosteroids. Mayo Clin Proc 2006;81(10):1361-7.
59. Jick SS, Lieberman ES, Rahman MU, Choi HK. Glucocorticoid use, other associated factors and the risk of tuberculosis. Arthritis & Rheumatism. 2006;55:19-26.
60. Fraser R, Ingram MC, Anderson NH, et al. Cortisol effects on body mass, blood pressure, and cholesterol in the general population. Hypertension 1999, 33:1364-8.
61. Souverein PC. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart 2004;90:859-865.
62. Gurwitz JH, Bohn RL, et al. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch intern med 1994;154(1):97-101.
63. Garbe E, LeLorier J, et al. Risk of ocular hypertension or open-angle glaucoma in elderly patients on oral glucocorticoids. Lancet 1997;3350(9083):979-82.
64. Curtis JR, Westfall AO. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum 2006;55(3):420-6.
65. Sullivan PW. Oral corticosteroid exposure and adverse effects in asthmatic patients. J Allergy Clin Immunol. 2018;141:110-6.
66. Stuijver DJF, Majoor CJ, van Zaane B, Souverein PC, de Boer A, Dekkers OM, Büller HR, Gerdes VEA. Use of oral glucocorticoids and the risk of pulmonary embolism. A population-based case-control study. CHEST 2013;143:1337-1342.
67. Sneeboer MMS, Majoor CJ, de Kievit A, Meijers JCM, van der Poll T, Kamphuisen PW, Bel EH. Prothrombotic state in patients with severe and prednisolone-dependent asthma. J Allergy Clin Immunol. 2016;137:1727-32.
68. Naber D. Psychopathological and neuropsychological effects of 8-days’ corticosteroid treatment. A prospective study. Psychoneuroendocrinology 1996;21(1):25-31.
General introduction and aims of the thesis
23
1